Company Overview and News

 
V-Guard Industries Limited - Allotment of ESOP/ESPS

2018-10-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Trading Window

2018-10-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries (₹190.9): Sell

2018-09-18 premium.thehindubusinessline
On Tuesday, the stock tumbled 5 per cent with above average volume, decisively breaking a key support at ₹197. The stock has been in a medium-term downtrend since encountering a significant resistance at ₹250 in April 2018. Following a corrective upmove, the stock met with resistance around ₹225 in late August and continued its downtrend. Since then, the stock has been in a short-term downtrend.
VGUARD 532953

 
V-Guard Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Shareholders meeting

2018-08-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
Check out insider trades for August 13; Bajaj Finance, Dabur, Yes Bank in focus

2018-08-17 moneycontrol
Chambal Fertilisers & Chemicals Ltd: Hindustan Times Ltd., (promoter) bought 10,000 shares through market purchase on August 13, 2018
YESBANK BAJFINANCE JAGRAN 532705 VGUARD 532648 BJJQY 538268 YYBKY WONDERLA 532953 500034

 
Crompton Greaves Consumer Electricals: In the spotlight

2018-08-11 premium.thehindubusinessline
Investors willing to bet on the country’s growing consumption theme can consider buying the stock of Crompton Greaves Consumer Electricals. All segments of the company — fans, lighting and pumps — have shown strong growth in the June quarter and, as a result, the company has had market share gains.
517354 HVLQY HAVELLS VGUARD 532953

 
V-Guard Industries Q1 standalone net up 47.9% to Rs 34.39 Cr

2018-08-01 moneycontrol
Consumer electrical and electronic appliances maker V-Guard Industries has clocked a 47.9 percent rise in standalone net profits for the April-June 30 2018 quarter to Rs 34.39 crore.
VGUARD 532953

 
V-Guard Industries Limited - Outcome of Board Meeting

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

 
V-Guard Industries Limited - Financial Result Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VGUARD 532953

4
Vedanta, Tata Motors, BoI, BEL, Dabur results

2018-07-30 thehindubusinessline
Over 70 companies will declare their April-June results on Tuesday. Among these are Ajanta Pharma, Bank of India, BASF India, BEL, Blue Dart Express, Cigniti Tech, Dabur India, EIH, Eimco, FACT, Federal Mogul, Future Market, GSFC, Huhtamaki, IIFL Holdings, JK Paper, LG Balakrishnan, Mahanagar Gas, Mangalore Chem, Morepen Labs, PowerGrid, Raymond, Snowman Logistics, Subex, Supreme Ind, Tata Motors, Uniphos Enterprises, UPL, Vedanta and V-Guard Industries.
500429 DABUR IIFL BASF 532636 DBRQY 532953 538635 532331 500096 UNIPHOS 532162 VGUARD AJANTPHARM 500570 500042 SNOWMAN TATAMOTORS 526612 BLUEDART JKPAPER TTM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...